AIDS vaccine development: Let a thousand flowers bloom

Journal of Clinical Pathology

Volumn 51, Issue 10, 1998, Pages 725-730

  Oxford, John S ^a   Addawe, M ^a   Lambkin, Robert ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CYTOTOXIC T LYMPHOCYTE; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOPATHOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS INFECTION;

EID: 0031785451     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.10.725     Document Type: Review

References (38)

1. McKinney RE. Antiretroviral therapy: evaluating the new era in HIV treatment. Adv Pediatr Infect Dis 1996;12:297-323.
2. Deeks S, Smith M, Kahn J. HIV-1 Protease inhibitors. JAMA 1997;277:145-53.
3. Stuart-Harris CH, Schild GC, Oxford JS. Influenza: the viruses and the disease. London: Edward Arnold, 1984.
4. Baker W, Rauberta R, Menegus M. Case control study of influenza vaccine effectiveness in preventing pneumonia hospitalization among older persons, Monroe County, New York, 1989-1992. In: Hanoun C, Kendal A, Klenk H, et al, eds. Options for the control of influenza II. Amsterdam: Elsevier, 1993.
5. Wilson SE, Habeshow JA, Oxford JS. HIV type 1 envelope glycoprotein 120 carboxyterminal peptide induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens. AIDS Res Hum Retrovir 1997;13:131-24.
6. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-8.
7. Kahn JO, Steimer KS, Baenziger J, et al. Clinical, immunologic, and virologie observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J Infect Dis 1995;171:1343-7.
8. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-8.
9. Igarashi T, Ami Y, Yamamoto H, et al. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. J Gen Virol 1997;78: 985-9.
10. Stott EJ, Chan WL, Mills KH, et al. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990; 336:1538-41.
11. StahlHennig C, Dittmer U, Nisslein T, et al. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol 1996;77:2969-81.
12. SL, Polacino P, Stallard V, et al. Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection. Immunol Lett 1996;51: 115-19.
13. Honda M, Matsuo K, Nakasone T, et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci USA 1995;92:10693-7.
14. Arnold GF, Resnick DA, Smith AD, et al. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Intervirology 1996;39:72-8.
15. Ghiara JB, Ferguson DC, Satterthwait AC, et al. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J Mol Biol 1997,266:31-9.
16. Ahlers JD, Dunlop N, Pendleton CD, et al. Candidate Hiv type-1 multideterminant cluster peptide-P18mn vaccine constructs elicit type-1 helper T-cells, cytotoxic T-cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retrovir 1996;12:259-72.
17. Wang B, Dang K, Agadjanyan MG, et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 1997;15:821-5.
18. Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med 1997;3:651-8.
19. Levine AM, Groshen S, Allen J, et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:351-64.
20. Race E, Frezza P, Stephens DM, et al. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. Vaccine 1995;13:54-60.
21. Race E, Stein CA, Wigg MD, et al. A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine. Vaccine 1995;13: 1567-75.
22. Habeshaw J, Wilson S, Oxford J. How HIV-1 lentivirus causes immune deficiency disease. Med Hypotheses (in press).
23. Nyambi P, Nkengasong J, Lewi P, et al. Multivariate analysis of human immunodeficiency virus type 1 neutralisation data. J Virol 1996;70:6235-43.
24. Baba TW, Trichel AM, An L, et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science 1996;272:1486-9.
25. Daniel M, Kirchoff F, Czajak S, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-41.
26. Almond N, Kent K, Cranage M, et al. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995;345:1342-4.
27. Rud E, Ogilvie L, Clarke B. A naturally attenuated SIVmac32H: vaccine or viral interference? In: Brown F, Chanock R, Ginsberg H, et al, eds. Vaccines 94. New York: Cold Spring Harbour, 1994:217-33.
28. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-91.
29. Chakrabarti BK, Maitra RK, Ma XZ, et al. A candidate live inactivatable attenuated vaccine for AIDS. Proc Natl Acad Sci USA 1996;93:9810-15.
30. Kestler HW, Chakrabarti BK. A live-virus "suicide" vaccine for human immunodeficiency virus. Cleve Clin J Med 1997; 64:269-74.
31. Abimiku AG, Franchini G, Tartaglia J, et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med 1995;1:321-9.
32. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-401.
33. Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993;12:777-83.
34. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: a novel approach to immunization. Int J Immunopharmacol 1995;17:79-83.
35. Boyer JD, Ugen KE, Wang B, et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination [see comments], Nature Med 1997;3: 526-32.
36. Levantis P, Lambkin R, Oxford J. Viral drug resistance. In: Hayes J, Wolf C, eds. Molecular genetics of drug resistance. Amsterdam: Harwood, 1997:81-138. (Evans H, ed. Modern genetics, vol 3).
37. Levantis P, Lambkin R, Oxford J. Viral drug resistance. In: Hayes J, Wolf C, eds. Molecular genetics of drug resistance. Amsterdam: Harwood, 1997:81-138. (Evans H, ed. Modern genetics, vol 3).
38. Baltimore D. In: An interview with David Baltimore. IAVI report; Newsletter on International AIDS Vaccine Research 1997;2:6-11.